Clinical Trial

Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study

Study acronym: DEWI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II study will evaluate dostarlimab with a watch-and-wait approach for patients with localized mismatch repair deficiency (dMMR)/microsatellite instability (MSI) gastric or oeso-gastric junction adenocarcinoma. The goal of the study is to determine whether the surgery could be avoided in patients with localized dMMR/MSI-H gastric/OGJ adenocarcinoma with complete response at endoscopy and biopsies free of tumoral cells after treatment with dostarlimab, with a watch-and-wait approaches.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-26; most recent amendment 2024-02-02.
Status change: Not Yet Recruiting → Recruiting 2024-02-02
Trial Details
NCT Number NCT06059495
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions Adenocarcinoma - GEJ, Gastric Adenocarcinoma
Enrollment 59 participants
Start Date 2023-12-18
Primary Completion 2028-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-02-05